Arcturus Therapeutics (ARCT) to Release Quarterly Earnings on Monday

Arcturus Therapeutics (NASDAQ:ARCT) is projected to release its Q1 2025 earnings data after the market closes on Monday, May 12th. Analysts expect Arcturus Therapeutics to post earnings of ($1.10) per share and revenue of $25.64 million for the quarter.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.78). Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The company had revenue of $22.77 million during the quarter, compared to analysts’ expectations of $44.64 million. On average, analysts expect Arcturus Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Arcturus Therapeutics Stock Down 3.5 %

Shares of Arcturus Therapeutics stock opened at $10.98 on Friday. Arcturus Therapeutics has a twelve month low of $8.04 and a twelve month high of $45.00. The firm has a market cap of $297.79 million, a PE ratio of -4.95 and a beta of 2.36. The business has a 50-day moving average price of $11.87 and a 200 day moving average price of $15.48.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ARCT. HC Wainwright reiterated a “buy” rating and set a $60.00 price objective on shares of Arcturus Therapeutics in a research report on Thursday, April 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a report on Friday, March 7th. BTIG Research set a $48.00 price target on shares of Arcturus Therapeutics and gave the stock a “buy” rating in a research note on Monday, March 10th. Wells Fargo & Company reduced their target price on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday, March 7th. Finally, Canaccord Genuity Group decreased their price target on Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating for the company in a report on Monday, March 10th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Arcturus Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $59.20.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.